Foundation Medicine, Inc.
NEWS
Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
Three years after acquiring a majority stake Foundation Medicine, Pharma giant Roche has agreed to buy up all outstanding shares for about $2.4 billion and bring the company’s sequencing diagnostics platform under the Roche umbrella.
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
A look at the latest batch of FDA approvals this year.
Boston Business Journal pulled together a list of the 25 biggest gainers in the state for 2017, and five of them are biopharma companies.
The addition of Pellini means the San Diego-based firm launched earlier this year can increase its investing pace and tap his healthcare experience as an executive at Foundation.
Foundation Medicine’s sequencing diagnostics test for solid tumors that can detect cancer-causing mutations in 324 genes was approved by the FDA Thursday.
JOBS
IN THE PRESS